Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2017

Published : Aug-2017

No. of Pages : 44

order by fax Inquire before Buying request discount

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
GlobalData Clinical Trials Report Coverage 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials 18
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials 29
Prominent Drugs 31
Latest Clinical Trials News on Familial Chylomicronemia (Type I Hyperlipoproteinemia) 32
Jul 11, 2017: New Data Reveal Hidden Burden of Familial Chylomicronaemia Syndrome 32
Clinical Trial Profile Snapshots 33
Appendix 42
Abbreviations 42
Definitions 42
Research Methodology 43
Secondary Research 43
About GlobalData 44
Contact Us 44
Source 44

List of Tables
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region, 2017* 7
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 13
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017* 14
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 15
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 19
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase, 2017* 21
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 30
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 31

List of Figures
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region (%), 2017* 7
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 11
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 12
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 13
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017* 15
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017* 18
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 21
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 22
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 26
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 31
GlobalData Methodology 43

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2017

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027